Attovia Therapeutics, Inc. (ATTO)
NASDAQ: ATTO · Real-Time Price · USD
13.83
-0.67 (-4.62%)
Oct 23, 2026, 4:00 PM EDT - Market closed
Attovia Therapeutics Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Attovia Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $42.2. The average 1-year stock price forecast is 205.13% higher than the current stock price, while the lowest is $30 (+116.92%) and the highest is $52 (+275.99%).
Price Target: $42.2 (+205.13%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Attovia Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|
| Strong Buy | 2 | 3 | 3 |
| Buy | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citi | Citi | Buy Maintains $30 | Buy | Maintains | $30 | +116.92% | Oct 14, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $45 | Buy | Maintains | $45 | +225.38% | Sep 3, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Reiterates $39 | Buy | Reiterates | $39 | +182.00% | Sep 3, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $45 | Buy | Maintains | $45 | +225.38% | Sep 3, 2026 |
Financial Forecast
Revenue This Year
462.50K
from 1.35M
Decreased by -65.74%
Revenue Next Year
n/a
from 462.50K
Decreased by -100.00%
EPS This Year
-3.45
EPS Next Year
-2.38
from -3.45
EPS and Forward PE are based on non-GAAP adjusted numbers.